Advertisement

Topics

Chugai's Emicizumab Receives Priority Review Designation by FDA for Hemophilia A with Inhibitors

01:00 EDT 24 Aug 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that the US Food and Drugs Administration (FDA) has accepted the Biologics License Application (BLA) and has granted Priority Review for an investigational anti...

Other Sources for this Article

For Media
Chugai Pharmaceutical Co., Ltd.
Media Relations Group, Corporate Communications Dept.,
Koki Harada
Tel: +81-3-3273-0881
E-mail: pr@chugai-pharm.co.jp
***
For US media
Chugai Pharma USA Inc.
Casey Astringer
Tel: +1-908-516-1350
E-mail: pr@chugai-pharm.com
***
For Investors
Chugai Pharmaceutical Co., Ltd.
Investor Relations Group, Corporate Communications Dept.,
Toshiya Sasai
Tel: +81-3-3273-0554
E-mail: ir@chugai-pharm.co.jp

NEXT ARTICLE

More From BioPortfolio on "Chugai's Emicizumab Receives Priority Review Designation by FDA for Hemophilia A with Inhibitors"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Food
Food is any substance consumed to provide nutritional support for the body. It is usually of plant or animal origin, and contains essential nutrients, such as carbohydrates, fats, proteins, vitamins, or minerals. The substance is ingested by an organism ...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...